Disodium carbenicillin and gentamicin sulfate have both shown promise in the treatment of infections caused by Pseudomonas aeruginosa. This study was designed to explore possible synergistic relationships among the new as well as the established antimicrobial agents used to treat such infections. With an agar dilution technique, minimum inhibitory concentrations of 27 strains of P. aeruginosa were determined in two-dimensional tests. Graphs of equal biological activity (isobolograms) demonstrated moderate synergistic effects of the carbenicillingentamicin combination over therapeutically feasible concentration ranges. In contrast, the combination of carbenicillin and polymyxin B showed only additive or slightly antagonistic effects. Tests of bacterial killing confirmed the presence of carbenicillin-gentamicin synergy in 3 of 6 strains of P. aeruginosa, but did not show true antagonism between carbenicillin and polymyxin B. Clinical trials of both drug combinations are advisable to determine whether therapeutic results can be improved, and whether the dosages of gentamicin or polymyxin B can thereby be reduced to lessen their toxic hazards.
Gentamicin sulfate, a potent aminoglycoside antibiotic, has recently been made commercially available after a lengthy period of clinical investigation. Because of its broad spectrum of activity against commonly encountered gram-negative bacilli, including Pseudomonas aeruginosa, gentamicin promises to be an exceedingly useful drug. Its nephrotoxic and neurotoxic properties became apparent early in the course of initial clinical investigations, and appear to be of the same order of magnitude as kanamycin sulfate (4, 6, 8, 9, 12) .
Carbenicillin, disodium a-carboxybenzylpenicillin, is a semisynthetic derivative of 6-aminopenicillanic acid closely related to ampicillin. In contrast to other penicillins, carbenicillin possesses moderate in vitro activity against certain gram-negative bacilli not susceptible to ampicillin, particularly P. aeruginosa, indole-positive proteus species, and Serratia marcescens (1, 3, 5, 15) . The order of activity against P. aeruginosa is small, however, requiring the intravenous administration of 20 to 40 g per day to achieve the necessary serum levels of 100 to 400 Ag/ml.
This study was undertaken to explore possible 1 Presented in part at the 69th Annual Meeting of the American strains to the two drug combinations as determined both by agar-dilution and bacterial-killing tests. Not only was there no correlation in the pattern of response to the two drug pairs but also no correlation in response as measured by the two tests of drug interaction.
DISCUSSION
The isobologram of the carbenicillin-gentamicin combination carried out by two-dimensional agar dilution tests suggested a degree of synergistic activity which was clarified somewhat by the studies of bacterial killing. Three of six strains showed true antibacterial synergism, which, although not marked, might prove useful clinically. The combined effect of these two drugs in the remaining three strains showed neither synergism nor antagonism, but even an additive effect might also prove useful clinically.
The apparent antagonism between carbenicillin and polymyxin B shown in the isobologram could not be confirmed by tests of bacterial killing, at least with the drug concentrations used in these experiments. As with gentamicin, either an additive or a synergistic effect might have therapeutic application.
The lack of correlation between the two tests of drug interaction used in this study is understandable only when it is considered that different end points are being measured. It is possible that by carrying the tests of bacterial killing out for 12 to 18 hr or by varying the drug concentrations used, or both, different results might have been obtained.
In their initial report on carbenicillin, Brumfitt, Percival, and Leigh (5) described synergy between carbenicillin and gentamicin in all four strains of P. aeruginosa that they examined; they also observed synergistic effects in their test strains when carbenicillin was combined with colistin or streptomycin. Standiford and associates (16) also reported a synergistic effect of the carbenicillin-gentamicin combination against Pseudomonas strains. Smith and co-workers (14) , using a checkerboard microtiter tube dilution technique, found carbenicillin-gentamicin synergy in 5 of 10 strains of P. aeruginosa examined, and carbenicillin-polymyxin B synergy in the 5 strains not showing synergy with the former drug pair. This interesting observation could not be confirmed in the present study, in which no predictive relationship was observed among the responses of these two drug pairs.
The apparent synergy between dicloxacillin and ampicillin has been well documented in the past by Sutherland and Batchelor (18) and by Sabath and Abraham (13) . The mechanism of this synergistic effect is recognized to be due to competitive inhibition of /3-lactamase through binding to a f-lactamase-resistant penicillin (dicloxacillin), allowing the 3-lactamase-sensitive analogue (ampicillin) to remain free to exert its antibacterial effect.
No such synergy could be demonstrated with the combination of carbenicillin and dicloxacillin. This is in agreement with the early reports of Brumfitt et al. (5) , and of Acred et al. (1) , who stated that carbenicillin is not inactivated by 0-lactamase produced by P. aeruginosa. A combination of carbenicillin and dicloxacillin would therefore not be expected to show synergism.
Whether true antibacterial synergism can be demonstrated is perhaps somewhat less significant than the fact that the activity of carbenicillin combined with gentamicin can be expected to be at least additive in nature. Although the agardilution test demonstrated antagonism between carbenicillin and polymyxin B in 6 of 27 strains, the degree of antagonism was not great, and its clinical significance is not known. In vitro screening of this combination would be prudent prior to initiating therapy in a given patient.
Clinical trials of carbenicillin combined with either gentamicin sulfate or polymyxin B sulfate appear to be warranted for several reasons. First, results of therapy of systemic Pseudomonas infections with any of the currently available drugs used singly leave ample room for improvement. Second, several recent reports have emphasized the ease with which strains of P. aeruginosa may become resistant to carbenicillin, both in vitro and in vivo (2, 15) . Finally, the addition of carbenicillin to therapy with either gentamicin or polymyxin B may permit some reduction in dosage of the latter two drugs, thereby reducing the concomitant risk of toxicity.
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